SI3332789T1 - Režim zdravljenja s kladaribinom za zdravljenje multiple skleroze - Google Patents

Režim zdravljenja s kladaribinom za zdravljenje multiple skleroze

Info

Publication number
SI3332789T1
SI3332789T1 SI200532305T SI200532305T SI3332789T1 SI 3332789 T1 SI3332789 T1 SI 3332789T1 SI 200532305 T SI200532305 T SI 200532305T SI 200532305 T SI200532305 T SI 200532305T SI 3332789 T1 SI3332789 T1 SI 3332789T1
Authority
SI
Slovenia
Prior art keywords
multiple sclerosis
treating multiple
cladribine
regimen
cladribine regimen
Prior art date
Application number
SI200532305T
Other languages
English (en)
Inventor
Luca Giampiero De
Amaud Ythier
Alain Munafo
Maria Lopez-Bresnahan
Original Assignee
Merck Serono Sa, Centre Industriel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3332789(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono Sa, Centre Industriel filed Critical Merck Serono Sa, Centre Industriel
Publication of SI3332789T1 publication Critical patent/SI3332789T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SI200532305T 2004-12-22 2005-12-20 Režim zdravljenja s kladaribinom za zdravljenje multiple skleroze SI3332789T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22
EP18151634.5A EP3332789B1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
SI3332789T1 true SI3332789T1 (sl) 2022-08-31

Family

ID=36227798

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200532191T SI2805723T1 (sl) 2004-12-22 2005-12-20 Režim kladribina za zdravljenje multiple skleroze
SI200532305T SI3332789T1 (sl) 2004-12-22 2005-12-20 Režim zdravljenja s kladaribinom za zdravljenje multiple skleroze

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200532191T SI2805723T1 (sl) 2004-12-22 2005-12-20 Režim kladribina za zdravljenje multiple skleroze

Country Status (24)

Country Link
US (2) US7713947B2 (sl)
EP (6) EP2275110B1 (sl)
JP (7) JP5795456B2 (sl)
KR (1) KR20070091662A (sl)
AR (1) AR052830A1 (sl)
AU (2) AU2005318190B2 (sl)
BR (1) BRPI0517132B8 (sl)
CA (2) CA3087419C (sl)
CY (3) CY1112614T1 (sl)
DK (2) DK2805723T3 (sl)
EA (1) EA015799B1 (sl)
ES (1) ES2921858T3 (sl)
FR (1) FR18C1008I2 (sl)
HR (1) HRP20120228T1 (sl)
HU (2) HUE059133T2 (sl)
IL (2) IL183930A0 (sl)
LT (2) LT3332789T (sl)
LU (1) LUC00064I2 (sl)
MX (1) MX2007007610A (sl)
NO (1) NO20073813L (sl)
PL (3) PL1827461T3 (sl)
SG (1) SG160391A1 (sl)
SI (2) SI2805723T1 (sl)
WO (1) WO2006067141A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2649810A1 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2011117267A1 (en) 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
JP2021504363A (ja) 2017-11-24 2021-02-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 進行型多発性硬化症の処置における使用のためのクラドリビン処方計画
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
PL321431A1 (en) 1994-12-22 1997-12-08 Ortho Pharma Corp Soluble 2-chloro-2'deoxyadenosine compositions
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
US7572909B2 (en) 2002-09-25 2009-08-11 Brigham Young University Method for the preparation of 2-halo-2′-deoxyadenosine compounds from 2′-deoxyguanosine
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
CN1761471A (zh) * 2003-02-25 2006-04-19 应用研究系统Ars股份公司 利巴韦林与干扰素β在脱髓鞘疾病中的联用
EA009714B1 (ru) 2003-03-28 2008-02-28 Арес Трейдинг С.А. Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
RS20050735A (en) 2003-03-28 2008-06-05 Ares Trading S.A., Cladribine formulations for improved oral and transmucosal delivery
CA2649810A1 (en) * 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis

Also Published As

Publication number Publication date
CY2018006I2 (el) 2018-06-27
AU2011200768B2 (en) 2012-09-13
BRPI0517132B8 (pt) 2021-05-25
PL2805723T3 (pl) 2018-04-30
AU2011200768A1 (en) 2011-03-17
US20090081163A1 (en) 2009-03-26
JP6092945B2 (ja) 2017-03-08
CY1112614T1 (el) 2016-02-10
EP2275110A2 (en) 2011-01-19
ES2921858T3 (es) 2022-09-01
WO2006067141A1 (en) 2006-06-29
IL183930A0 (en) 2007-10-31
LUC00064I2 (sl) 2018-03-28
LTPA2018503I1 (lt) 2018-03-12
EP2275110A3 (en) 2011-04-27
JP2015180685A (ja) 2015-10-15
HRP20120228T1 (hr) 2012-04-30
DK2805723T3 (da) 2018-01-29
US7713947B2 (en) 2010-05-11
BRPI0517132B1 (pt) 2020-02-18
JP5795456B2 (ja) 2015-10-14
EP2263678B1 (en) 2014-06-11
JP5908863B2 (ja) 2016-04-26
EA015799B1 (ru) 2011-12-30
US8377903B2 (en) 2013-02-19
JP6290962B2 (ja) 2018-03-07
NO20073813L (no) 2007-09-21
JP6430554B2 (ja) 2018-11-28
US20100203017A1 (en) 2010-08-12
JP2008524313A (ja) 2008-07-10
EP1827461B1 (en) 2012-02-29
EP2805723B1 (en) 2018-01-17
CY1119790T1 (el) 2018-06-27
IL212421A (en) 2014-01-30
EA200701221A1 (ru) 2008-02-28
EP2805723A1 (en) 2014-11-26
JP2016138128A (ja) 2016-08-04
AU2005318190A1 (en) 2006-06-29
EP2263678A3 (en) 2011-04-27
AU2005318190B2 (en) 2010-11-25
LUC00064I1 (sl) 2018-02-14
JP2013216664A (ja) 2013-10-24
CA2588966C (en) 2020-07-21
EP4070800A1 (en) 2022-10-12
CA3087419C (en) 2023-03-07
CY2018006I1 (el) 2018-06-27
SI2805723T1 (sl) 2018-02-28
FR18C1008I2 (fr) 2019-03-01
CA3087419A1 (en) 2006-06-29
CA2588966A1 (en) 2006-06-29
MX2007007610A (es) 2007-08-03
KR20070091662A (ko) 2007-09-11
IL212421A0 (en) 2011-06-30
EP3332789B1 (en) 2022-04-06
JP2018165271A (ja) 2018-10-25
LT3332789T (lt) 2022-07-25
JP2017101061A (ja) 2017-06-08
DK3332789T3 (da) 2022-07-11
EP2275110B1 (en) 2013-07-10
EP2263678A2 (en) 2010-12-22
PL3332789T3 (pl) 2022-08-22
EP1827461A1 (en) 2007-09-05
LTC2805723I2 (lt) 2022-04-25
FR18C1008I1 (sl) 2018-03-30
HUE059133T2 (hu) 2022-10-28
SG160391A1 (en) 2010-04-29
AR052830A1 (es) 2007-04-04
EP3332789A1 (en) 2018-06-13
JP2020193206A (ja) 2020-12-03
PL1827461T3 (pl) 2012-07-31
BRPI0517132A (pt) 2008-09-30
HUS1800009I1 (hu) 2018-05-02

Similar Documents

Publication Publication Date Title
HUS1800009I1 (hu) Kladribin adagolási elõírás szklerózis multiplex kezelésére
ZA200808852B (en) Cladribine regimen for treating multiple sclerosis
IL179139A0 (en) Method for treating multiple sclerosis
HK1203055A1 (en) Treatment for multiple sclerosis
IL183900A0 (en) Polymerization processes
EP1741656A4 (en) ELEVATOR
EP1741658A4 (en) LIFT DEVICE
EP1812665A4 (en) MACHINE FOR HEAVY-HEAD EXTRACTION FOR CUTTED SURFACES
EP1798006A4 (en) ROBOT
IL180446A0 (en) Object process graph application controller-viewer
EP1792865A4 (en) ELEVATOR
EP1792864A4 (en) LIFT DEVICE
TWI367216B (en) Process for stopping continuous polymerization
EP1754680A4 (en) LIFT DEVICE
EP1741659A4 (en) LIFT DEVICE
EP1795483A4 (en) LIFT DEVICE
GB2411101B (en) Glove
EP1790611A4 (en) ELEVATOR EQUIPMENT
EP1741657A4 (en) LIFT DEVICE
EP1783085A4 (en) LIFT APPARATUS
EP1741660A4 (en) ELEVATOR
EP1792867A4 (en) ELEVATOR
EP1783088A4 (en) LIFT DEVICE
EP1754679A4 (en) ELEVATOR EQUIPMENT
EP1724229A4 (en) LIFT DEVICE